Overview
Apitegromab (Scholar Rock) is a research-grade peptide compound that has attracted significant attention in the scientific community for its role in bioactive optimization. Anti-pro/latent myostatin antibody developed by Scholar Rock. Selectively blocks myostatin activation rather than the mature ligand, offering a targeted approach to myocyte differentiation.
This compound belongs to the bioactive category of research peptides and has been the subject of numerous preclinical investigations. Its unique molecular properties make it a valuable tool for researchers exploring novel therapeutic pathways.
Apitegromab (SRK-015) is a monoclonal antibody with a novel mechanism: it binds pro-myostatin and latent myostatin, preventing proteolytic activation by furin and BMP-1/tolloid proteases. Unlike antibodies targeting mature myostatin, apitegromab acts upstream — blocking the conversion of inactive precursors to the active differentiation-inhibiting ligand. This selectivity avoids interference with other TGF-β family members (GDF-11, activins). Currently in clinical trials for spinal muscular atrophy (SMA) and myocyte-related research models. The growing body of published literature continues to expand our understanding of this compound's potential applications in laboratory settings.
Mechanism of Action
Apitegromab (SRK-015) is a monoclonal antibody with a novel mechanism: it binds pro-myostatin and latent myostatin, preventing proteolytic activation by furin and BMP-1/tolloid proteases. Unlike antibodies targeting mature myostatin, apitegromab acts upstream — blocking the conversion of inactive precursors to the active differentiation-inhibiting ligand. This selectivity avoids interference with other TGF-β family members (GDF-11, activins). Currently in clinical trials for spinal muscular atrophy (SMA) and myocyte-related research models.
The signaling pathways activated by Apitegromab (Scholar Rock) continue to be mapped through proteomic and transcriptomic analyses. Current research focuses on identifying the specific receptor subtypes and downstream effectors responsible for the observed biological responses. Understanding these molecular interactions is critical for advancing the compound from preclinical investigation toward potential translational applications.
Research Areas
- Growth hormone secretion pathway analysis
- Neurotrophic factor expression research
- Receptor binding kinetics
- Hormonal axis modulation
- Signal transduction research
Compound Specifications
| CAS Number | Proprietary (Scholar Rock SRK-015) |
| Purity | Recombinant, ≥95% SDS-PAGE |
| Storage | 2–8 °C. Do not freeze. Protect from light. |
| Category | Bioactive |
| Price | €185 |
| Format | Research reference, inquire |
Available Formats
- Research vial — contact for availability
Dissolution
Use our dilution calculator for precise concentration calculations.